JGC
AVNS icon

J. Goldman & Co’s Avanos Medical AVNS Stock Holding History

J. Goldman & Co’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-452,448
Closed -$5.54M – 462
2025
Q2 		$5.54M Buy
452,448
+133,579
+42% +$1.68M 0.13% 191
2025
Q1 		$4.57M Buy
+318,869
New +$4.98M 0.11% 219
2024
Q4 		– Sell
-72,541
Closed -$1.74M – 461
2024
Q3 		$1.74M Hold
72,541
– – 0.05% 242
2024
Q2 		$1.45M Sell
72,541
-14,015
-16% -$273K 0.04% 275
2024
Q1 		$1.72M Sell
86,556
-150,098
-63% -$2.9M 0.06% 233
2023
Q4 		$5.31M Buy
236,654
+5,522
+2% +$114K 0.21% 121
2023
Q3 		$4.67M Buy
+231,132
New +$5.24M 0.16% 139

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

J. Goldman & Co's AVNS Position: Q3 2025 in Review

J. Goldman & Co sold out of Avanos Medical (AVNS) in Q3 2025, closing a stake of 452,448 shares — an estimated $5.54M sold.

J. Goldman & Co first reported a position in AVNS in Q3 2023 and held it in 7 quarters. The position peaked at $5.54M in Q2 2025. 276 funds tracked by Wall St. Rank hold AVNS as of Q3 2025.

  • J. Goldman & Co reported no remaining Avanos Medical position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 452,448 Avanos Medical shares in Q3 2025, an estimated $5.54M.
  • J. Goldman & Co first reported a position in Avanos Medical in Q3 2023 and held it in 7 quarters.
  • J. Goldman & Co's Avanos Medical position peaked at $5.54M in Q2 2025.
  • 276 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.